SCHEMBL18632523

SCHEMBL18632523

O=c1[nH]nc2ccc(-c3cccc(-c4c(F)cccc4F)c3)cn12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.52
PDPK1 O15530 1/20 0.46
NOTUM Q6P988 5/20 0.38
HAO2 Q9NYQ3 1/20 0.36
CHEK1 O14757 3/20 0.36
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36
GRM2 Q14416 1/20 0.36
RET P07949 1/20 0.34
MET P08581 1/20 0.34
LTK P29376 1/20 0.34
GRK5 P34947 1/20 0.34
CDK8 P49336 1/20 0.34
RPS6KA3 P51812 1/20 0.34
MST1R Q04912 1/20 0.34
TYRO3 Q06418 1/20 0.34
DYRK1A Q13627 1/20 0.34
LRRK2 Q5S007 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
ALK Q9UM73 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18632534 0.86 SCN5A (0.54) SCN5APDPK1NOTUMMKNK1MKNK2
SCHEMBL18632538 0.86 SCN5A (0.57) SCN5APDPK1NOTUMCHEK1GRM2
SCHEMBL253974 0.83 SCN5A (0.57) SCN5APDPK1NOTUMCHEK1MKNK1
SCHEMBL18632525 0.81 SCN5A (0.51) SCN5APDPK1NOTUMMKNK1MKNK2
SCHEMBL18632514 0.80 SCN5A (0.50) SCN5APDPK1NOTUMCHEK1GRM2
SCHEMBL18632535 0.79 SCN5A (0.62) SCN5APDPK1NOTUMCHEK1GRM2
SCHEMBL18632530 0.79 SCN5A (0.62) SCN5APDPK1NOTUMCHEK1GRM2
SCHEMBL18642506 0.77 SCN5A (0.45) SCN5APDPK1NOTUMCHEK1GRM2
SCHEMBL18632526 0.76 SCN5A (0.47) SCN5APDPK1NOTUMCHEK1GRM2
SCHEMBL18632511 0.73 LTK (0.55) SCN5ANOTUMCHEK1GRM2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease OAT, XDH, MAPT SCN5A 1311/4885PDPK1 2343/4885NOTUM 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.